AegirBio
AegirBio AB is a Swedish diagnostics company focused on developing innovative home testing solutions for oral health, therapeutic drug monitoring, and infectious diseases. The company has established a platform that enhances lateral flow tests, significantly improving their sensitivity and precision compared to traditional methods. AegirBio's product lineup includes the Veritope technology, which measures intact natalizumab for multiple sclerosis, alongside the MagniaReader, designed for both research and veterinary use. Their advancements enable robust, affordable, and easy-to-use testing instruments applicable across human health, veterinary, food safety, and environmental sectors. By leveraging novel techniques, AegirBio aims to expand the market for lateral flow tests and enhance patient care through more reliable diagnostics.
Viraspec
Acquisition in 2020
Viraspec AB, founded in 2020 and based in Lund, Sweden, specializes in the development and commercialization of rapid diagnostic tests for COVID-19. As a subsidiary of AegirBio AB, Viraspec focuses exclusively on point-of-care testing, creating a simple and robust platform for analyzing blood and saliva samples to detect the presence of antibodies and the virus itself. The company's diagnostic platform employs a test device that collects blood samples and provides results quickly and accurately, facilitating efficient patient diagnosis and treatment. By delivering faster, cost-effective, and reliable results, Viraspec aims to enhance the response to COVID-19 and improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.